Poster Abstracts • OFID 2018:5 (Suppl 1) • S555 pump refilled each day at an outpatient infusion center. All seven patients were infected with P. aeruginosa (four being MDR) with one patient co-infected with E. coli. Susceptibility testing was performed on three P. aeruginosa isolates (two susceptible and one intermediate Methods. We created a survey of eight patient scenarios culled from the OPAT records of Tufts Medical Center. Six case scenarios had clinical equipoise, while two control scenarios had a clear indication for discharge with intravenous antibiotics. Infectious diseases attendings affiliated with Tufts Medical Center were surveyed. Respondents were asked preferences for oral vs. intravenous antibiotics for each scenario, their confidence in each decision, and demographics. Providers' antibiotic scores equaled the sum of responses to the six case scenarios (1 point for intravenous, 0 points for oral). Self-assessments of confidence in each decision were on a scale of 0 to 100% (100% indicating complete confidence).
"OPAT providers" = MDs who see OPAT patients as outpatients.
Conclusion.
Although in reality all six case scenario patients had been discharged on intravenous antibiotics, respondents chose oral antibiotics almost 50% of the time. This pilot study demonstrates potential for antibiotic stewardship regarding intravenous recommendations.
Disclosures. All authors: No reported disclosures. October 6, 2018: 12:30 PM Background. Hospital admission is a key cost driver in ABSSSI patients. Data suggest many ABSSSI patients are unnecessarily hospitalized and can be effectively and safely managed as outpatient (OP) at substantially lower cost. ORI a single-dose treatment has the potential to shift care from the inpatient (IP) to the OP setting in selected patients. In phase III trials, a single dose of ORI had comparable efficacy and safety to twice daily VAN for 7-10 days in ABSSSI patients who were treated in OP. Real-world comparative data on outcomes in ABSSSI patients using ORI in OP are limited. This study sought to compare the 30 day hospital admission rates and mean (standard deviation (SD)) healthcare costs among ABSSSI patients who received ORI or VAN as an OP.
Comparisons of 30-Day Admission and 30-Day
Methods. Retrospective cohort analysis of ORI and VAN patients in the Truven Health MarketScan ® Databases in 2016. Inclusion criteria: age ≥18 years; OP claim for ORI or VAN (index day (d) ); a diagnosis of skin infection ≤7 d prior and 3 d after the index day; no IP discharge in 3 d prior to index day; Background. Studies of vancomycin (VANC) and piperacillin-tazobactam (VPT) induced acute kidney injury (AKI) have included diverse populations obscuring clinical generalizations. To our knowledge, previous studies have omitted combat-related trauma patients despite frequent exposure to broad-spectrum antimicrobials. Our objective was to analyze whether combination therapy with VPT was associated with an increased risk of AKI compared with VANC and other broad-spectrum β-lactam antibiotics (VBL).
Methods. Patients within the Trauma Infectious Disease Outcomes Study (TIDOS) who received ≥48 hours concomitant VPT or VBL started within 24 hours of each other were assessed. Exclusion criteria were receipt of renal replacement therapy and baseline creatinine >1.5 mg/dL or missing. Based on prior studies, AKI was defined by meeting any of the RIFLE, AKIN or Vanc Consensus Guidelines criteria 3-7 days after therapy initiation. Glomerular Filtration Rate (GFR) was calculated using Modification of Diet in Renal Disease (MDRD) equation.
Results. Of 2692 patients, 39 patients who received VPT and 197 who received VBL (172 meropenem, 17 imipenem-cilastatin, and 8 cefepime) were included with median ages of 25 and 24 years old, respectively. Initial median GFRs were 138mL/ minute in both groups. Gender distribution was equal with 97% males receiving VPT and 99% VBL. Thirty-five (90%) patients in VPT and 186 (94%) in VBL had an Injury Severity Score>15 (P = 0.28). Median duration of VANC therapy was 6 and 8 days for VPT and VBL (P = 0.36). Injuries were sustained in Afghanistan in 82% treated with VPT and 92% with VBL (P = 0.06). The groups differed by US-based hospital (P = 0.06), and presence of blast injury which was more common in VBL (P < 0.001). In the VBL group, incidence of AKI was 9.1% compared with 12.8% in the VPT group (P = 0.55). Median time to AKI was 6 days (IQR 5-6) for those receiving VPT and 4 days (IQR 3-6) for VBL. Background. Outpatient parenteral antibiotic therapy (OPAT) is an integral part of infectious disease (ID) management. The IDSA OPAT guidelines stress the importance of monitoring outcomes and safety assessment, yet there is no prescribed method to execute this process. There is limited published data on effective OPAT monitoring strategies in the US healthcare system.
Conclusion.
Methods. To monitor and measure outcomes of patients on OPAT, our multi-disciplinary re-design team built a tracking system and database into the existing electronic medical record (EMR). A data entry form, called an "episode of care (EOC), " is completed in the EMR by the ID physician at the time of consultation (see figure) . Data include: consultant's name, discharge location, antibiotic type, duration of treatment, lab monitoring recommendations, and outpatient (OP) follow-up visit date. This information automatically populates three items: the hospital interagency referral, a dashboard for active monitoring by outpatient providers, and a database for quality metric analysis. Outcomes measured include emergency room (ER) visits 30-days post discharge, 30-day re-admission rates, clinic no -show rates, and adverse events. Patients discharged on IV antibiotics with no EOC (i.e., no ID oversight) were also identified.
Results. In a 6-month period after the initiation of the new tracking system at our institution, 515 patients were discharged from the hospital on OPAT with an EOC. An additional 197 were discharged on IV antibiotics and no EOC. Of the patients with an EOC 25.5% had an ED visit within 30 days of discharge, and 19% had a 30-day re-admission from time of discharge. There were 20 adverse events related to antibiotic therapy documented (9 laboratory abnormalities, 6 antibiotic side-effects, 3 line complications, 1 episode of clostridium difficile, and 1 incorrect/missed antibiotic). Nineteen patients had a no-show to their first ID follow-up appointment.
Conclusion. We demonstrate the feasibility of integrating a tracking system for patients on OPAT into a pre-existing EMR and creating a database for assessment of outcomes. We also identify a significant number of patients discharged without ID oversight, revealing missed opportunities for ID input in these cases. Background. Serious pediatric infections are treated safely with outpatient parenteral or prolonged oral antibiotic therapy (OPAT). The OPAT delivery system can be complex with outcomes complicated by social vulnerabilities in the lives of children on OPAT. Our goal was to better understand the psycho-social challenges pediatric families face undergoing OPAT.
Disclosures. All authors: No reported disclosures.

Health-Related Social Vulnerabilities in a Pediatric
Methods. Caregivers of patients discharged on parenteral or prolonged oral antibiotics and referred to Doernbecher Children's Hospital OPAT program between July 1, 2017 and December 31, 2017 were eligible for enrollment. We assessed health-related social vulnerabilities using a pre-discharge survey of pediatric caregivers.
Child-specific medical information was collected by EMR review. Descriptive statistics were used to characterize social challenges.
Results. Twenty-six caregivers completed the survey. Mean patient age was 7.7 years. Infections included osteomyelitis (31%), endocarditis or infectious thrombophlebitis (19%), brain abscess or meningitis (15%), complicated pneumonia (12%), device-related infections (12%), or other (12%). Combined, patients spent 1,150 days on OPAT (390 parenteral; 760 prolonged oral antibiotic days). Of the social vulnerabilities endorsed, economic hardship featured prominently with 31% of caregivers having difficulty paying for food, housing or utilities and 12% having problems with appliances working at home. Among the caregivers, 23% reported inadequate social support, 42% reported psychological problems (31% anxiety; 19% depression), 15% reported involvement with child protective services, and 19% reported other legal concerns. 27% had difficulty getting time off work and 31% requested extra help with coordination of healthcare services. 58% of caregivers had a high school degree or less.
Conclusion. We identified a large number of social vulnerabilities that likely impact pediatric OPAT care after discharge. Identifying social vulnerabilities for pediatric OPAT patients prior to discharge, such as health literacy or barriers to return visits, could better enable treatment customization or prompt care coordination that better supports pediatric OPAT patients.
Disclosures. Methods. We performed a quality improvement project of all patients initiated on OPAT during admission to Yale New Haven Hospital between October 1, 2016 and September 30, 2017. Descriptive data were collected. Healthcare utilization according to discharge location was assessed in older (age ≥65 years) vs. younger (age <65 years) adults in the 6 months following OPAT initiation. Differences between groups were assessed using x 2 and t tests. Results. We identified 450 patients initiated on OPAT. Table 1 shows descriptive characteristics. Median OPAT duration was 31 days (range 1-155) for older adults and 34 days (range 1-183) for younger adults. Discharge to skilled nursing facility (SNF) was more likely in older (71%, N = 139/197) vs. younger (42%, N = 105/253) adults (P < 0.0001) following OPAT initiation. However, there was no difference in healthcare utilization according to discharge location (Table 2 ). Healthcare utilization was also similar between older and younger adults across antimicrobials (Figure 1) .
Conclusion. Regardless of discharge home vs. SNF, there was no difference in healthcare utilization between older and younger adults. These findings affirm the safety of home OPAT in older adults. 
